- Trials with a EudraCT protocol (370)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
370 result(s) found for: Nursing diagnosis.
Displaying page 7 of 19.
EudraCT Number: 2009-012185-32 | Sponsor Protocol Number: ML22413 | Start Date*: 2009-11-23 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: Open label, multicentric phase IIIb study to evaluate the effect of tocilizumab in combination with DMARDs in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated b... | |||||||||||||
Medical condition: Moderate to severe active rheumatoid arthritis (RA), who are inadequate responders to DMARDs. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019709-41 | Sponsor Protocol Number: GFM-Aza-ceplene | Start Date*: 2010-10-13 | |||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies | |||||||||||||
Full Title: A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interl... | |||||||||||||
Medical condition: Myelodysplastic syndromes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001409-18 | Sponsor Protocol Number: HMR2016-0.6 | Start Date*: 2016-12-06 | |||||||||||
Sponsor Name:Helse More og Romsdal Hospital Trust | |||||||||||||
Full Title: A prospective, open randomized, parallel-group study to evaluate the outcome of discontinuing or continuing anti-tumor necrosis factor treatment in patients with ulcerative colitis in sustained cli... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002360-30 | Sponsor Protocol Number: NA-1-009 | Start Date*: 2021-01-05 | |||||||||||||||||||||||||||||||
Sponsor Name:NoNO Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants with Acute Ischemic Stroke Under... | |||||||||||||||||||||||||||||||||
Medical condition: Acute ischemic stroke (AIS) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) NO (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005177-21 | Sponsor Protocol Number: HGS1006-C1056 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) AT (Completed) CZ (Completed) ES (Completed) SK (Completed) SE (Completed) NL (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005733-37 | Sponsor Protocol Number: SB2-G31-RA | Start Date*: 2013-08-16 | |||||||||||
Sponsor Name:Samsung Bioepis Co., Ltd. | |||||||||||||
Full Title: A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects with Moderate t... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LT (Completed) BG (Completed) LV (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000835-84 | Sponsor Protocol Number: 30982081-CAP-3001 | Start Date*: 2006-10-10 | |||||||||||
Sponsor Name:Jansen-Cilag International N.V. | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Ceftriaxone with/without Linezolid in Treatment of Subjects Hospitalized With Community-Acquired Pneumonia | |||||||||||||
Medical condition: Hospitalized community acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) HU (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003785-14 | Sponsor Protocol Number: 200249 | Start Date*: 2014-03-03 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma | ||||||||||||||||||
Medical condition: Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000576-42 | Sponsor Protocol Number: ICORG12-01 | Start Date*: 2012-04-05 | |||||||||||
Sponsor Name:Cancer Trials Ireland | |||||||||||||
Full Title: S1007, A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer ... | |||||||||||||
Medical condition: Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004704-19 | Sponsor Protocol Number: MK-7625A-036 | Start Date*: 2019-08-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | |||||||||||||
Full Title: A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nos... | |||||||||||||
Medical condition: Nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) EE (Trial now transitioned) Outside EU/EEA GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000568-41 | Sponsor Protocol Number: GS-US-417-0301 | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to ... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) GB (Completed) BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005625-29 | Sponsor Protocol Number: VERI-305-AMIO | Start Date*: 2008-03-06 | |||||||||||
Sponsor Name:Cardiome Pharma Corp. | |||||||||||||
Full Title: A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation | |||||||||||||
Medical condition: Treatment of Atrial fibrillation (AF). AF is the most common arrhythmia encountered in clinical practice. It is usually associated with age and general physical condition, rather than with a speci... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) LT (Completed) EE (Completed) DK (Completed) CZ (Completed) FI (Completed) SK (Completed) LV (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000345-55 | Sponsor Protocol Number: A4021016 | Start Date*: 2008-06-05 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street New York, NY 10017 | |||||||||||||
Full Title: RANDOMIZED, OPEN LABEL, PHASE III TRIAL OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN VERSUS PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER | |||||||||||||
Medical condition: Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) AT (Prematurely Ended) FR (Completed) ES (Completed) HU (Completed) DE (Completed) IE (Completed) CZ (Prematurely Ended) SK (Completed) IT (Prematurely Ended) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007648-85 | Sponsor Protocol Number: HGS1006-C1074 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. | |||||||||||||
Full Title: A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 ... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) NL (Completed) BE (Completed) GB (Completed) CZ (Completed) ES (Completed) IT (Completed) SE (Completed) SK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003630-25 | Sponsor Protocol Number: GS-US-417-0304 | Start Date*: 2017-06-15 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Trial now transitioned) BE (Completed) CZ (Completed) DE (Trial now transitioned) PL (Completed) ES (Completed) BG (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003539-31 | Sponsor Protocol Number: EORTC-1635-BTG | Start Date*: 2019-06-04 | ||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | ||||||||||||||||||
Full Title: IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT – A phase III study | ||||||||||||||||||
Medical condition: Histologically WHO grade II (diffuse) or III (anaplastic) astrocytoma, IDHmt without 1p/19q co-deletion (local diagnosis) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) AT (Completed) NO (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000914-76 | Sponsor Protocol Number: 1409R2121 | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:Shionogi Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Unc... | |||||||||||||
Medical condition: Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis caused by Gram-negative Pathogens | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed) DE (Completed) PL (Completed) RO (Completed) HR (Completed) LV (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004800-40 | Sponsor Protocol Number: AT1001-041 | Start Date*: 2012-01-25 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease. | |||||||||||||
Medical condition: Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the gene (GLA) that encodes the lysosomal enzyme α-galactosidase A. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) DK (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001048-73 | Sponsor Protocol Number: BAY41-6551/13084 | Start Date*: 2013-07-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Pati... | |||||||||||||
Medical condition: Gram-negative pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004066-28 | Sponsor Protocol Number: AMLSG2415 | Start Date*: 2018-04-04 |
Sponsor Name:University Hospital Ulm | ||
Full Title: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplas... | ||
Medical condition: Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome wi... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
